Checkout
Cart: $0.00 - (0 items )

This Company Wants to Rewrite the Future of Genetic Disease

This Company Wants to Rewrite the Future of Genetic Disease



Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

Source: www.wired.com
This Company Wants to Rewrite the Future of Genetic Disease

Back to top